fda warning letter compounded semaglutide september 2025 Navigating Semaglutide: What Health Care Providers Need to Know The FDA sent a warning
Description
Zepbound (Tirzepatide): Approved in 2023 for chronic weight management
D.PrescottE
[DOI] [PMC free article] [PubMed] [Google Scholar] 78.Laurindo L.F., Barbalho S.M., Guiguer E.L., da Silva Soares de Souza M., de Souza G.A., Fidalgo T.M., Arajo A.C., de Souza Gonzaga H.F., de Bortoli Teixeira D., de Oliveira Silva Ullmann T., et al
2 GLP-1 RAs reduce major adverse cardiovascular events (MACE), including acute myocardial infarction, stroke, and mortality, in patients with multiple cardiovascular risk factors
Others: GIPR/GLP-1R dual agonists and GIPR/GLP-1R/GCGR triagonists Intestinal endocrine K cells produce gastric inhibitory polypeptide (GIP)
